BACKGROUND: Despite improvements in medical and surgical therapy, infective endocarditis (IE) is still associated with a severe prognosis and remains a therapeutic challenge. We aimed to evaluate the impact of a standardized diagnostic and therapeutic protocol on mortality and to correlate the outcome with compliance with our management-based protocol. METHODS: We conducted an observational before-after study that included 333 consecutive patients treated for IE at a referral center from 1991 to 2006, which was divided into 2 periods: period 1 (1991-2001), before implementation of our therapeutic protocol (n = 173), and period 2 (2002-2006), after implementation of our protocol (n = 160). Our protocol was created by a multidisciplinary task force including a sampling of biological specimens, the use of only 4 antimicrobial agents, a standardized duration of treatment, standardized surgical indications, and 1 year of close follow-up. Because our protocol was based on a local consensus by physicians and surgeons, it was not possible to randomize the study. RESULTS: The 1-year mortality significantly decreased from 18.5% during period 1 to 8.2% during period 2 (hazard ratio, 0.41; 95% confidence interval, 0.21-0.79 [P = .008]). After multivariable analysis, the management during period 2 remained a strong protective factor (adjusted hazard ratio, 0.26; 95% confidence interval, 0.09-0.76 [P = .01]). During period 2, we observed a statistically significantly better compliance in antimicrobial therapy and fewer cases of renal failure. Deaths by embolic events and multiple organ failure syndrome also significantly decreased during period 2. CONCLUSION: A dramatic reduction in mortality was observed during this study, suggesting that a management-based approach has a significant impact on IE outcome.
BACKGROUND: Despite improvements in medical and surgical therapy, infective endocarditis (IE) is still associated with a severe prognosis and remains a therapeutic challenge. We aimed to evaluate the impact of a standardized diagnostic and therapeutic protocol on mortality and to correlate the outcome with compliance with our management-based protocol. METHODS: We conducted an observational before-after study that included 333 consecutive patients treated for IE at a referral center from 1991 to 2006, which was divided into 2 periods: period 1 (1991-2001), before implementation of our therapeutic protocol (n = 173), and period 2 (2002-2006), after implementation of our protocol (n = 160). Our protocol was created by a multidisciplinary task force including a sampling of biological specimens, the use of only 4 antimicrobial agents, a standardized duration of treatment, standardized surgical indications, and 1 year of close follow-up. Because our protocol was based on a local consensus by physicians and surgeons, it was not possible to randomize the study. RESULTS: The 1-year mortality significantly decreased from 18.5% during period 1 to 8.2% during period 2 (hazard ratio, 0.41; 95% confidence interval, 0.21-0.79 [P = .008]). After multivariable analysis, the management during period 2 remained a strong protective factor (adjusted hazard ratio, 0.26; 95% confidence interval, 0.09-0.76 [P = .01]). During period 2, we observed a statistically significantly better compliance in antimicrobial therapy and fewer cases of renal failure. Deaths by embolic events and multiple organ failure syndrome also significantly decreased during period 2. CONCLUSION: A dramatic reduction in mortality was observed during this study, suggesting that a management-based approach has a significant impact on IE outcome.
Authors: Sadao Jinno; Barbara M Gripshover; Tracy L Lemonovich; James M Anderson; Michael R Jacobs Journal: J Clin Microbiol Date: 2010-10-06 Impact factor: 5.948
Authors: Ciara Keane; Helen Petersen; Kieran Reynolds; Debra K Newman; Dermot Cox; Howard F Jenkinson; Peter J Newman; Steven W Kerrigan Journal: Arterioscler Thromb Vasc Biol Date: 2010-11-11 Impact factor: 8.311
Authors: Paola A Erba; Gilbert Habib; Andor W J M Glaudemans; Jose M Miro; Riemer H J A Slart Journal: Eur J Nucl Med Mol Imaging Date: 2017-07 Impact factor: 9.236
Authors: Paola Anna Erba; Patrizio Lancellotti; Isidre Vilacosta; Oliver Gaemperli; Francois Rouzet; Marcus Hacker; Alberto Signore; Riemer H J A Slart; Gilbert Habib Journal: Eur J Nucl Med Mol Imaging Date: 2018-05-24 Impact factor: 9.236
Authors: K de With; F Allerberger; S Amann; P Apfalter; H-R Brodt; T Eckmanns; M Fellhauer; H K Geiss; O Janata; R Krause; S Lemmen; E Meyer; H Mittermayer; U Porsche; E Presterl; S Reuter; B Sinha; R Strauß; A Wechsler-Fördös; C Wenisch; W V Kern Journal: Infection Date: 2016-06 Impact factor: 3.553
Authors: J Champey; P Pavese; H Bouvaist; M Maillet; A Kastler; B Boussat; P Francois Journal: Eur J Clin Microbiol Infect Dis Date: 2016-09-06 Impact factor: 3.267